Press Releases
Jun 21, 2010
Dako and Omnyx Sign Agreement within Digital Pathology
Dako, a Danish based world leader in tissue-based cancer diagnostics, and Omnyx, a leader in digital pathology solutions, announced today that they have entered into a three-year agreement to develop clinical algorithms for digital pathology. The aim is to support pathologists in generating even more accurate, objective and reproducible diagnostic results.
Read MoreMar 16, 2010
Dako: New diagnostic tests provide hope for patients with stomach cancer
Dako announced today that two of its products have obtained a CE-mark as diagnostic tests for selecting patients with metastatic stomach (gastric) cancer who may benefit from Herceptin™ treatment. Dako’s HercepTest™ and HER2 FISH pharmDx™ enable physicians to identify the unique group of cancer patients that might benefit from the drug. New research suggests that patients with metastatic stomach cancer live longer when treated with the drug.
Read MoreMar 2, 2010
Dako achieves all-time high revenue and operating profit in 2009
Today, Dako announced its annual results 2009 and the Danish based company presents the highest ever revenues and earnings in its history.
Read MoreJan 18, 2010
AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
AstraZeneca and Dako Denmark A/S announced today that they have entered into a collaboration agreement to develop companion diagnostic tests for multiple AstraZeneca oncology projects, including biologics and small molecules, in various stages of discovery and development.
Read More